55112-89-5

Usage

Safety Profile

Poison by intraperitoneal andsubcutaneous routes. When heated to decomposition itemits very toxic fumes of NOx and HCl.

InChI:InChI=1/C8H17Cl2N.ClH/c1-2-3-6-11(7-4-9)8-5-10;/h2-8H2,1H3;1H

Upstream product

• 102-79-4 n-butyldiethanolamine 

Downstream Products

• 42520-97-8 butyl-bis-(2-chloro-ethyl)-amine 
• 212770-83-7 1-butyl-4-(4-methoxy-benzenesulfonyl)-piperidine-4-carboxylic acid ethyl ester 
• 239797-82-1 1-n-butyl-4-(4-butoxybenzenesulfonyl)piperidine-4-carboxylic acid ethyl ester 
• 239797-46-7 1-butyl-4-[4-(4-chlorophenoxy)benzenesulfonyl]piperidine-4-carboxylic acid ethyl ester 
• 212770-84-8 1-butyl-4-(4-methoxy-benzenesulfonyl)-piperidine-4-carboxylic acid 
• 239797-83-2 1-n-butyl-4-(4-butoxybenzenesulfonyl)piperidine-4-carboxylic acid 
• 239797-47-8 1-butyl-4-[4-(4-chlorophenoxy)benzenesulfonyl]piperidine-4-carboxylic acid 
• 129992-45-6 N-n-Butyl-N'-(4-pentyloxyphenyl)-piperazine 
• 106896-77-9 1-Butyl-4-(3-methoxy-phenyl)-piperidine-4-carbonitrile 

Relevant academic research and scientific papers

Synthesis and structure - Activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis

The matrix metalloproteinases (MMPs) are a family of zinc-containing endopeptidases that play a key role in both physiological and pathological tissue degradation. In our preceding paper, we have reported on a series of novel and orally active N-hydroxy-α-phenylsulfonylacetamide derivatives. However, these compounds had two drawbacks (moderate selectivity and chirality issues). To circumvent these two problems, a series of novel and orally active N-substituted 4-benzenesulfonylpiperidine-4-carboxylic acid hydroxyamide derivatives have been synthesized. The present paper deals with the synthesis and SAR of these compounds. Among the several compounds synthesized, derivative 55 turned out to be a potent, selective, and an orally active MMP inhibitor in the clinically relevant advanced rabbit osteoarthritis model. Detailed pharmacokinetics and metabolism data are described.

Synthesis and Mesogenic Properties of N-n-alkyl-N'-(4-n-Pentyloxyphenyl)-Piperazines

The N-n-alkyl-N'-(4-n-pentyloxyphenyl)-piperazines (4) exhibit ordered smectic phases at temperatures below 100 deg C.For 3, 4, 5 and 6 carbons in the alkyl chain, two smectic phases are present and for 7, 8 and 9 carbons only one smectic phase is present.The ΔH values for 4, 5, 6 and 7 carbons are anomalous.From optical and X-ray data, the smectic phases are identified as probably smectic E and B phases.